Johnny Makhoul, MD
Cardiovascular Disease · Owensboro, KYNPI 1831183714
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novartis at 42.4% of the total. Reporting peaked in 2019 at $747 and has fallen 84.8% since, to $113 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in KY, where the typical reported total is $2,503.
Across 145 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Johnson & Johnson$378
- Amgen$316
- Pfizer$126
- Abbott$98
- Boehringer Ingelheim$82
- plus $490 from 15 others
What the payments were for
- Food & beverage$2,589100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 62 | $1,099 |
| Johnson & Johnson | 27 | $378 |
| Amgen | 11 | $316 |
| Pfizer | 7 | $126 |
| Abbott | 3 | $98 |
| Boehringer Ingelheim | 6 | $82 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Boston Scientific | 3 | $56 |
| Amarin Pharma, Inc. | 4 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $44 |
| Intuitive Surgical | 1 | $44 |
| AstraZeneca | 2 | $39 |
| Edwards Lifesciences | 1 | $39 |
| Cardinal Health 200 LLC | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $11 |
How this compares
$2,589 in reported general payments places this provider in the 50th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $103,681 |
| EntrestoSacubitril/Valsartan | 20 | $29,513 |
| JardianceEmpagliflozin | 15 | $12,058 |
| Metoprolol Succinate | 102 | $1,409 |
| Rosuvastatin Calcium | 183 | $1,299 |
| Atorvastatin Calcium | 82 | $708 |
| Losartan Potassium | 85 | $701 |
| Amiodarone Hcl | 19 | $503 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 64 | $365 |
| Potassium Chloride | 23 | $323 |
| Carvedilol | 54 | $267 |
| Amlodipine Besylate | 75 | $264 |
| ClopidogrelClopidogrel Bisulfate | 34 | $264 |
| Ezetimibe | 13 | $255 |
| Metoprolol Tartrate | 80 | $254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $126 | $103,681109 claims |
| NovartisEntresto | $1,099 | $29,51320 claims |
| Boehringer IngelheimJardiance | $82 | $12,05815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Owensboro
- Madhura MylaOwensboro$58K
- Kishor VoraOwensboro$21K
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- William SkinnerLexington$312K
- Prabodh MehtaElizabethtown$133K
- John HarrisLouisville$129K
- David MoliternoLexington$115K
- Rohan SamsonLouisville$94K
- Srinivasa AppakonduHazard$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.